SEC Comment Letter for Viskase Holdings, (VISK) — Dec 29, 2025
Viskase Holdings, Inc.
Date: Dec. 29, 2025 · CIK: 0000727510 · Accession: 0000000000-25-011845
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Enzon Pharmaceuticals, Inc. Draft Registration Statement on Form S-4 Submitted December 19, 2025 CIK No. 0000727510 Dear Richard L. Feinstein:
December 29, 2025
Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Enzon Pharmaceuticals, Inc. 20 Commerce Drive, Suite 135 Cranford, NJ 07016
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Todd E. Mason, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> December 29, 2025 Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Enzon Pharmaceuticals, Inc. 20 Commerce Drive, Suite 135 Cranford, NJ 07016 Re: Enzon Pharmaceuticals, Inc. Draft Registration Statement on Form S-4 Submitted December 19, 2025 CIK No. 0000727510 Dear Richard L. Feinstein: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Todd E. Mason, Esq. </TEXT> </DOCUMENT>